Citations

Showing 10 of 108152 citations.

PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST‐AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION‐FREE SURVIVAL – ANALYSIS FROM THE TOURMALINE‐MM3 STUDY
Goldschmidt, Hartmut , Weisel, K., Chng, W-J, Suryanarayan, Kaveri , Teng, Zhaoyang , Labotka, Richard, Mateos, MV, Dimopoulos, Meletios Α. , Rajkumar, S. Vincent , Moreau, Philippe , Mikala, Gábor , Cavo, Michèle , Ramasamy, Karthik

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 632-633

10.1097/01.hs9.0000563804.33885.3f Get It

Background:Deepened response has been associated with prolonged progression‐free (PFS) and overall survival in multiple myeloma, including in the maintenance therapy setting. In the Myeloma XI trial, post‐ASCT maintenance with lenalidomide vs observation resulted in improved responses in 15.8% vs 11.0% of patients (pts) and a median PFS of 56.9 vs 30.1 months (Jackson et al, ASH 2017). In the phase 3, double‐blind, placebo‐controlled TOURMALINE‐MM3 study (NCT02181413), post‐ASCT maintenance therapy with the oral proteasome inhibitor (PI) ixazomib vs placebo resulted in a 39% improvement in PFS (median 26.5 vs 21.3 months; HR 0.72; 95% CI: 0.58–0.89; p = 0.002), with a favorable safety profile (Dimopoulos et al, Lancet 2019). We report improvements in depth of response and the impact on outcomes in TOURMALINE‐MM3.Aims:To evaluate the rates and timing of response improvement during ixazomib vs placebo maintenance and the impact on PFS in TOURMALINE‐MM3.Methods:Pts who had achieved ≥partial response (PR) to induction therapy with a PI and/or immunomodulatory drug followed by single ASCT were randomized 3:2 to receive ixazomib (N = 395) or placebo (N = 261) on day 1, 8, and 15 of 28‐d cycles for up to 2 years or until progressive disease or unacceptable toxicity. Randomization was stratified by induction regimen, pre‐induction ISS stage, and post‐ASCT response (complete response [CR] or very good PR [VGPR] vs PR). Ixazomib dose was 3 mg in cycles 1–4 and 4 mg from cycle 5 if tolerated in cycles 1–4. Minimal residual disease (MRD) was assessed at screening by flow cytometry (10–5 sensitivity). The primary endpoint was PFS per independent review committee (IRC). Other endpoints included rate of response improvement in pts enrolled in VGPR or PR.Results:At study entry, 60 (15%), 213 (54%), and 89 (23%) pts in the ixazomib arm and 54 (21%), 152 (58%), and 35 (13%) in the placebo arm had CR, VGPR, and PR, respectively, by IRC. Deepening responses were seen in 139/302 (46%) ixazomib vs 60/187 (32%) placebo pts with VGPR/PR at enrollment (relative risk [RR] 1.41, 95% CI 1.1–1.8, p = 0.004), including 92/213 (43%) vs 48/152 (32%) VGPR to CR (RR 1.37, p = 0.025) and 47/89 (53%) vs 12/35 (34%) PR to VGPR/CR (RR 1.54, p = 0.063). On Kaplan‐Meier analysis of time to best deepened response in VGPR/PR pts (Figure), 24‐month rates of deepening response were 54.2% vs 41.4%, and there was a 38.4% improvement in the chance of deepening response over time with ixazomib vs placebo (HR 1.384, p = 0.034). A pooled analysis across arms among pts enrolled in VGPR/PR showed that deepening response vs no improvement was associated with prolonged PFS (median not reached vs 15.9 months; HR 0.245, 95% CI 0.184–0.325, p < 0.0001). Analysis by treatment arm showed that, in VGPR/PR pts with deepening response, 24‐month PFS rates were 77.4% vs 68.3% with ixazomib vs placebo (medians not reached; HR 0.875; 12.5% risk reduction; 95% CI 0.52–1.47; p = 0.615); in VGPR/PR pts without deepening response 24‐month PFS rates were 33.4% vs 23.6% (median 17.9 vs 14.1 months; HR 0.780; 22% risk reduction; 95% CI 0.59–1.03; p = 0.080). Baseline MRD status was a strong predictor of deepening response; deepening responses were seen in 63% (78/124) vs 32% (94/293) of MRD‐ vs MRD+ pts enrolled in VGPR/PR.Summary/Conclusion:Post‐ASCT maintenance with ixazomib resulted in a significantly higher rate of deepening response vs placebo; deepening response was associated with prolonged PFS. Ixazomib resulted in non‐significant PFS benefit vs placebo in VGPR/PR pts with and without deepening response; prolonged follow‐up would be needed to confirm these results.image
PB2155 ONLINE CME SIGNIFICANTLY IMPACTS MULTIPLE MYELOMA CLINICIANS: EXPERIENCE FROM A MULTI‐YEAR CURRICULUM WITH 33,699 LEARNERS
Willis, Lauren , TANZOLA, MELINDA, Lucero, Katie , Cason, C L, Harvey, Rachel , Stewart, A. Keith, Vij, Ravi , Faiman, Beth M , Harvey, R. D., Lonial, Sagar , Landgren, Ola

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 968-969

10.1097/01.hs9.0000567104.86214.98 Get It

Background:The treatment paradigm for multiple myeloma (MM) has evolved rapidly following new drug approvals and combinations. These improvements have the potential to improve outcomes for patients, but only if specialists in hematology/oncology (hem/oncs) have up‐to‐date knowledge on selection of treatments, prevention and management of adverse events (AEs), and comfort with emerging clinical trial data.Aims:We sought to determine if a curriculum of online continuing medical education (CME) activities could improve hem/onc knowledge and competence in treating patients with MM.MethodsThis analysis included hem/onc data from a MM curriculum spanning over 4 years, with 54 activities. For each year of the curriculum, an expert panel identified knowledge/competence gaps to be addressed through CME. Within the analysis, assessment questions were grouped into learning topics and the average for pre and post‐education was calculated for 2016‐2018 of the curriculum for each topic. The analysis elucidated the impact of the curriculum on narrowing gaps in knowledge/competence using a pre/post design. Statistical significance was assessed using a chi‐square statistic (P < .05 level).Results:As of December 2018, the curriculum had reached 33,699 US hem/onc learners and 2144 participated in the outcomes assessment. Treatment Selection: The curriculum significantly improved hem/onc knowledge/competence over time for selecting treatment for patients with relapsed/refractory (R/R) MM (pre/post: 2016, 41%/51%, P < .001; 2018, 48%/64%, P < .001). Managing AEs: The curriculum led to sustained knowledge gains for hem/oncs over time related to managing treatment‐related AEs in patients with MM (pre/post: 2016, 39%/53%, P < .001; 2018, 80%/84%, P = .427). Knowledge of Clinical Trial Data: Activities within the curriculum also significantly improved hem/onc knowledge of clinical trial data for consolidation and maintenance therapy (pre/post: 2016, 63%/76%, P < .001; 2017, 68%/74%, P < .05; 2018, 62%/76%, P < .001). Potential Patient Impact: The reach of Medscape Oncology CME has a large impact on how US hem/oncs treat patients with MM. Of all hem/onc specialists with MM diagnostic encounters, 64% are members of Medscape. Additionally, 70% of all high decile (deciles 7‐10) hem/onc specialists with MM diagnostic encounters are members of Medscape. Based on the number of learners for the curriculum and the average number of patient encounters, this education has the potential to impact 33,894 MM patient encounters.[IQVIA Data]Summary/Conclusion:This analysis shows that online CME, as part of a sustained educational curriculum, using various formats (video, text, panel discussion, case‐based) can significantly improve the knowledge and competence of hem/oncs in multiple areas related to MM. Statistically significant gains in knowledge and competence selecting treatment for R/R MM were seen even with the introduction of new clinical evidence in this area. The analysis also shows the potential impact on patients and the large reach that is achievable with online education. As new therapies and combinations of treatments continue to change practice, additional education is needed to aid hem/oncs in staying abreast of new data, managing AEs, and tailoring therapy selection for individual patients with MM.
PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY
Kumar, Shaji , Goldschmidt, Hartmut , Mateos, M.‐V., Mangiacavalli, Silvia , Min, Chang‐Ki , Esteves, Graça , Handa, Hiroshi , Rodríguez, Carlos Fernández de Larrea, Delforge, Michel , Durie, Brian G.M. , González‐Calle, Verónica , Du, Juan , Kım, Kihyun , Merlini, Giampaolo , Dimopoulos, Meletios Α. , Kastritis, Efstathios , Ludwig, Heinz , Escalante, Fernando , Cameron, Chris G , Haltner, Anja , Rajkumar, S. Vincent

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 234-235

10.1097/01.hs9.0000560548.93776.aa Get It

Background:Multiple myeloma (MM) is a heterogeneous disease with varying survival outcomes depending on the presence of certain genetic abnormalities. Common abnormalities include trisomies, translocations involving the chromosome 14, and amplifications or deletions of chromosomes 1, 13, and 17. t(11;14), occurring in 15% of patients with myeloma, had been considered a standard risk abnormality, but recent data suggest inferior outcome. This is important as new therapeutic options such as the BCL‐2 inhibitor venetoclax has been shown to be particularly effective in t(11;14) patients.Aims: Primary objective: To describe the overall survival of myeloma patients with translocation t(11:14) Secondary objectives: To determine the response rates, progression free survival, time to progression, time to next treatment, duration of responses and overall survival with different regimens among patients with t(11;14), to determine the prognostic factors for overall survival among patients with t(11;14), and to identify the spectrum of co‐existing genetic abnormalities among patients with t(11;14)Methods:This was a multicenter study to identify the outcomes of patients with t(11;14), using a retrospectively assembled cohort. Patients with MM diagnosed between 2005 and 2015 with t(11;14) identified on FISH performed within six months of diagnosis, and with treatment details available and if alive, a minimum of 12 months of follow up, were enrolled.Results:The current analysis includes 848 patients; median age of 64.4 years; 60.0% male. The median follow‐up from diagnosis for the entire cohort was 46.5 months; 86.7% of the patients were alive at the last follow up. ISS stage distribution included: Stage I (35.3%), Stage II (38.9%) and Stage III (25.8%). The distribution of FISH abnormalities included: del 13q (14.5%), 1q amp (12.1%), del 17p or monosomy 17 (6.1%). Initial therapy included different regimens: 23.3% had an IMiD, 43.3% had a PI, 20.0% had both and 13.3% had no novel agent. The drug classes by line of therapy are shown in Table 1. A stem cell transplant (SCT), defined as within 12 months of start of first line treatment, was used in 39.1% of patients. The median time to next treatment (TTNT) after initial treatment was 13.7 (95% CI: 11.3 to 16.5) months. The median overall survival (OS) from diagnosis for the entire cohort was 82.5 (95% CI: 73.5 to 95.8) months; 4‐year estimates for those diagnosed from January 2005 to December 2009, and from January 2010 to December 2014 were 75.1% and 70.2%, respectively. Median OS by initial regimen is shown in Figure 1; those receiving an early SCT had median OS of 116.9 (95% CI: 85.6 to NA) months.Summary/Conclusion:This is the first study to examine the outcomes of a large group of myeloma patients with t(11;14) abnormality. Patients receiving a combination of a PI and an IMiD appear to have the best survival outcomes. Patients receiving an early SCT appear to have excellent survival with median OS approaching 10 years. Additional patients are being accrued to this study and additional analysis examining the variables affecting response duration and survival will be presented.image
S865 CHANGE IN CLONE SIZE DOES NOT PREDICT RISK OF MAJOR ADVERSE VASCULAR EVENTS: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
Larratt, Loree, Go, RS, David, Daniel, Höchsmann, Britta , Gustovic, Philippe, Latour, Régis Peffault de , Kulasekararaj, Austin , Wilson, A., Kulagin, Alexander

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 387

10.1097/01.hs9.0000561740.44478.b8 Get It

Background:In paroxysmal nocturnal hemoglobinuria (PNH), the granulocyte clone size is often used as an indicator of disease severity. However, the prognostic value of changing clone size on clinical outcomes in PNH is not well understood.Aims:To assess the prognostic value of change in PNH granulocyte clone size on the risk of developing major adverse vascular events (MAVE) or high disease activity (HDA: elevated hemolysis [lactate dehydrogenase {LDH} ≥1.5 x upper limit of normal] and one or more PNH‐related symptom[s]) in patients with PNH.Methods:The International PNH Registry is the largest worldwide observational study of patients with a diagnosis of PNH or a detected PNH clone as low as 0.01%. This study assessed patients with a baseline value for PNH clone size (defined as the closest value to disease onset) and at least one additional clone size value, who were untreated with complement inhibitor therapy at enrollment, and had ≥12 months of untreated follow‐up. Patients were stratified by clone size at baseline and change in clone size was estimated using regression models of clone size vs duration from disease start, adjusted for baseline clone size. Patients were categorized as having stable, increasing, or decreasing clone size depending on the slope, where a change in clone size >10% per year was considered increasing/decreasing. Prognostic value of change in clone size was assessed using Poisson regression to estimate rate ratios of MAVE and logistic regression to estimate odds ratios of HDA during follow‐up, with stable clone size as the reference. Adjusted models included baseline LDH ratio category, history of bone marrow disease at baseline, baseline clone size, and duration.Results:As of April 3, 2018, a total of 1894 patients were available for analysis: cohort (COH) 1 (clone size >0.01% to ≤1%, n = 381); COH 2 (clone size >1% to ≤5%, n = 318); COH 3 (clone size >5% to ≤10%, n = 159); COH 4 (clone size >10% to ≤50%, n = 480); COH 5 (clone size >50% to ≤100%, n = 556). Median duration was 3.5 years. Clone size was stable in only 16.2% of patients, as compared with 45.3% increasing and 38.5% decreasing; stable clone size was primarily seen in patients with a clone size ≤1% at baseline (58% of patients in COH 1 with a stable clone), with less than 10% of patients with a stable clone in the other cohorts. Clone size change over time was highly prognostic of HDA; patients with increasing and decreasing clone size had an increased risk of HDA, compared to patients with stable clone size, although this may be due to patients with a stable clone largely in COH 1 with a low risk of HDA; after adjusting, we see no increased risk of HDA in patients with decreasing clone size, but the increased risk of HDA in patients with increasing clone size is maintained (Table). Due to limited data on covariates at baseline, only 156 patients were available for this adjusted analysis. There was no difference in the MAVE rate in patients with increasing or decreasing clone size as compared with those with a stable clone size. The lack of effect was maintained even after adjusting for covariates (Table).Summary/Conclusion:This is the first analysis of the prognostic value of PNH clone size changes on clinical outcomes over time in patients with PNH. Increasing clone size over time was predictive of patients experiencing HDA during their disease course. Interestingly, no difference in the MAVE rate was seen in patients with increasing or decreasing clone size, suggesting that change in clone size does not change the increased risk of MAVE in patients with PNH.image
Subconjunctival Dirofilariasis Presenting as Orbital Cellulitis
Shambhu, Smitha K., Murthy, Praveen R., D’Souza, Placid E., Hanumappa, Dhanalakshmi, Vikram, Holenarasipur R. , Janardhana, Geethanjali C., Matada, Roopashri, Vikram, Holenarasipur R.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | June 17, 2019 | Volume: 35 | Issue: 4 | Pages: e97-e99

10.1097/iop.0000000000001415 | PMID 31206462 Get It

Human ocular Dirofilariasis is a relatively rare, zoonotic disease, caused by a filarial nematode, Dirofilaria repens. This parasitic infestation usually presents as a subconjunctival nodule with hyperemia. The authors present a case of subconjunctival dirofilariasis in a 91-year-old gentleman, who presented with manifestations of orbital cellulitis. The live worm was surgically removed and identified to be D. repens.
Interfascicular Resection of Benign Peripheral Nerve Sheath Tumors
Stone, Jonathan J. , Puffer, Ross C. , Spinner, Robert J.

Mayo Clinic

JBJS Essential Surgical Techniques | June 17, 2019 | Volume: 9 | Issue: 2 | Pages: e18

10.2106/jbjs.st.18.00077 | PMID 31579536 Get It

Background: Interfascicular resection is a surgical technique used to safely treat benign peripheral nerve sheath tumors through careful dissection of functional neural elements off the tumor surface 1,2 . Description: Proper operative technique is essential to improving symptoms, preserving neurologic function, and minimizing the chance for recurrence. Accurate tumor localization, ideal patient positioning, and placement of a longitudinal incision permit adequate exposure. Prior to tumor resection, normal nerve should be identified proximally and distally and controlled with vessel loops. This allows functional fascicles streaming around the tumor in the pseudocapsule to be visualized during resection. A fascicle-free window is identified on the tumor surface through visual inspection and intraoperative neurophysiology monitoring if desired. The pseudocapsule layers are divided with a sharp instrument until a smooth and shiny true capsule layer is found. This plane should have minimal resistance and is developed circumferentially until the tumor can be enucleated in toto. At the poles of the tumor, a single nonfunctional nerve fascicle that courses into the tumor is typically found. If there is >1 fascicle running into the tumor, further pseudocapsule layers should be undermined to sweep fascicles off the true capsule surface. The entering-exiting fascicle can be tested for function and is cut sharply. The specimen should be sent to pathology for permanent sectioning. The sides of the pseudocapsule are spread in opposite directions to evaluate for residual tumor, and any remaining tumor is removed if it can be done safely. Meticulous hemostasis is achieved, and the surgical site is closed in anatomical layers. Alternatives: Pain is the most common presenting symptom, and neuroleptic medications should be used in escalating dosage prior to surgical intervention. Nonoperative medical therapy does not typically result in symptom freedom, and patients often opt for resection. For tumors that are suspected of being malignant, an image-guided percutaneous or open biopsy and staging (positron emission tomography and/or computed tomography scans of the chest, abdomen, and pelvis) are recommended prior to treatment planning. For symptomatic benign extremity lesions, surgical resection is the treatment of choice, and adjuvant therapies like radiation and/or chemotherapy are not recommended. For malignant lesions, more aggressive surgery (wide resection or amputation) and preoperative, intraoperative, or postoperative radiation with or without chemotherapy are often utilized. Rationale: The treatment approach depends on a variety of presenting features such as onset, progression, symptom severity, tumor size, location, imaging features, presence of a syndrome, and patient age. There is little benefit from the resection of an incidentally found, small, nongrowing lesion. The most common reasons for removal of extremity lesions are a painful mass and/or radiating “nerve” pain. There is a high likelihood of relieving the symptoms and minimizing the risk of recurrence, and a relatively low risk of causing neurologic injury. The procedure provides a definitive diagnosis. For patients with severe pain, progressive weakness, rapid tumor growth, or concerning imaging characteristics, biopsy should be considered to determine malignant potential.
Causes of Death in Status Epilepticus
English, Stephen , Mandrekar, Jay , Hocker, Sara E. , English, Stephen W, Mandrekar, Jay N., Hocker, Sara, Hawkes, Maximiliano A. , Rabinstein, Alejandro A.

Mayo Clinic

Critical Care Medicine | June 17, 2019 | Volume: 47 | Issue: 9 | Pages: 1226-1231

10.1097/ccm.0000000000003869 | PMID 31206357 Get It

Objectives: To determine the causes of death in patients with status epilepticus. To analyze the relative contributions of seizure etiology, seizure refractoriness, use of mechanical ventilation, anesthetic drugs for seizure control, and medical complications to in-hospital and 90-day mortality, hospital length of stay, and discharge disposition. Design: Retrospective cohort. Setting: Single-center neuroscience ICU. Participants: Patients with status epilepticus were identified by retrospective search of electronic database from January 1, 2011, to December 31, 2016. Interventions: Review of electronic medical records. Measurements and Main Results: Demographics, clinical characteristics, treatments, and outcomes were collected. Univariable and multivariable logistic regression analysis were used to determine whether the use of anesthetic drugs, mechanical ventilation, Status Epilepticus Severity Score, refractoriness of seizures, etiology of seizures, or medical complications were associated with in-hospital, 90-day mortality or discharge disposition. Among 244 patients with status epilepticus (mean age was 64 yr [interquartile range, 42–76], 55% male, median Status Epilepticus Severity Score 3 [interquartile range, 2–4]), 24 received anesthetic drug infusions for seizure control. In-hospital and 90-day mortality rates were 9.2% and 19.2%, respectively. Death was preceded by withdrawal of life-sustaining treatment in 19 patients (86.3%) and cardiac arrest in three (13.7%). Only Status Epilepticus Severity Score was associated with in-hospital and 90-day mortality, whereas the use of anesthetic drugs for seizure control, mechanical ventilation, medical complications, etiology, and refractoriness of seizures were not. Hospital length of stay was longer in patients with medical complications ( p = 0.0091), refractory seizures ( p = 0.0077), and in those who required anesthetic drugs for seizure control ( p = 0.0035). Patients who had refractory seizures were less likely to be discharged home (odds ratio, 0.295; CI, 0.143–0.608; p = 0.0009). Conclusions: In this cohort, death primarily resulted from the underlying neurologic disease and withdrawal of life-sustaining treatment and not from our treatment choices. Use of anesthetic drugs, medical complications, and mechanical ventilation were not associated with in-hospital and 90-day mortality.
The Value of SPECT/CT for Knee Osteoarthritis: A Systematic Review
Zarringam, Danial , Saris, Daniël B.F. , Bekkers, J.E.J. , Zarringam, D , Bekkers, J E J

Mayo Clinic

CARTILAGE | June 17, 2019 | Volume: 12 | Issue: 4 | Pages: 431-437

10.1177/1947603519855776 | PMID 31204483 Get It

Background Single photon emission computed tomography (SPECT/CT) is a diagnostic option for knee osteoarthritis patients without osteoarthritic features on X-ray; however, the added value of SPECT/CT remains debatable in the diagnostic algorithm. Objective To review the added value of SPECT/CT in the diagnostic algorithm of knee osteoarthritis. Study Design Systematic review Methods A systematic search was carried out in the databases EMBASE, MEDLINE, and the Cochrane collaboration. The retrieved articles were screened for relevance on title and abstract. This was followed by a full-text study quality appraisal of the remaining articles. Finally, a total of 9 trials were included. Results The use of SPECT/CT might objectify some clinical knee osteoarthritis symptoms. It could correlate with findings on plain radiography and magnetic resonance imaging. Furthermore, there is some evidence SPECT/CT gives additional information compared with these imaging modalities; however, superiority is not proven. The uptake on SPECT could predict the intraoperative macroscopic findings. Yet the clinical relevance remains unclear. Conclusion There is no strong evidence SPECT/CT should play a role in the diagnosing and decision-making processes of knee osteoarthritis. Yet there is evidence suggesting SPECT/CT might give additional information in the diagnosing process. More research would be of added value to answer this research question.
Tibial Plateau Cartilage Lesions: A Systematic Review of Techniques, Outcomes, and Complications
Melugin, Heath P. , Bernard, Christopher D. , Camp, Christopher L. , Saris, Daniël B.F. , Krych, Aaron J. , Krych, Aaron J , Camp, Christopher L. , Stuart, Michael J. , Nakamura, Norimasa

Mayo Clinic

CARTILAGE | June 17, 2019 | Volume: 13 | Issue: 1_suppl | Pages: 31S-41S

10.1177/1947603519855767 | PMID 31204491 Get It

Objective The purpose of this systematic review is to determine (1) current reported treatment options for isolated tibial plateau (TP) cartilage lesions, (2) patient reported outcomes following various treatments, and (3) complication rate and survivorship following various treatments. Design A literature search of PubMed, the Cochrane Library, and CINAHL was conducted adhering to PRISMA guidelines. Patients were included if they had TP cartilage lesions treated with surgery. Lesion characteristics, surgical procedure details, patient reported outcomes, complication, and failure rates were collected. Results Thirteen studies yielded 205 knees with TP cartilage lesions treated surgically. Ages ranged from 12 to 77 years. Surgical techniques included 138 treated with osteochondral allograft transplantation (OCA), 37 treated with osteochondral autograft transfer system (OATS), 11 treated with microfracture, 11 treated with an osteochondral scaffold, and 8 treated with autologous chondrocyte implantation (ACI). The patient-reported outcome measures were heterogeneous, but all reported improvements with the notable exception of one study evaluating microfracture. The rate of complications ranged from 0% to 4.6%. Failure rate ranged from 22% to 46% for OCA and 0% to 16% for OATS. No failures were reported for the additional techniques. Conclusions Various surgical techniques have been utilized for the treatment of TP cartilage lesions. Patient-reported outcome measures were heterogeneous, but improvements were reported following all surgical treatments except for microfracture, which resulted in decreased scores at mid-term follow-up. The complication rate was low for all techniques described. However, the failure rate was higher following unicondylar OCA for salvage treatment of posttraumatic deformities.
Bipolar Cartilage Lesions of the Knee: A Systematic Review of Techniques, Outcomes, and Complications
Melugin, Heath P. , Bernard, Christopher D. , Camp, Christopher L. , Saris, Daniël B.F. , Krych, Aaron J. , Camp, Christopher L. , Krych, Aaron J

Mayo Clinic

CARTILAGE | June 17, 2019 | Volume: 13 | Issue: 1_suppl | Pages: 17S-30S

10.1177/1947603519855761 | PMID 31204486 Get It

Objective The purpose of this systematic review was to determine (1) treatment options for bipolar cartilage lesions of the knee, (2) patient-reported outcomes following various surgical treatments, and (3) complication and failure rates following surgery. Design A literature search of PubMed, the Cochrane Library, and CINHAL was performed using PRISMA guidelines. Patients were included if they had bipolar cartilage lesions of the knee treated surgically. Lesion characteristics, surgical technique, patient-reported outcomes, complication rates, failure rates, and survivorship were recorded. Results Fourteen studies yielded 301 knees treated surgically. Patient age ranged from 15 to 74 years. Surgical techniques included 138 autologous chondrocyte implantation (ACI), 156 osteochondral allograft transplantation (OCA), and 7 osteochondral autograft transfer system (OATS). Seven studies reported a concomitant procedure rate that ranged from 0% to 88%. Eight studies reported that both reciprocal lesions received surgical treatment, while 6 studies did not specify. Lesion size ranged from 1 to 41 cm 2 . All reported postoperative improvements in patient-reported outcomes, but the measures were very heterogeneous. There were no major complications and the rate of minor complications ranged from 0% to 50%. Survivorship ranged from 40% to 100% for OCA, 76% to 95% for ACI, and 100% for the 1 study evaluating OATS. Conclusions Bipolar cartilage lesions of the knee typically involve a large surface area and are most commonly treated with ACI or OCA, while OATS may be an option for smaller lesions. Improvements in mid-term patient-reported outcomes were reported for all surgical procedures and they can be performed safely with a low rate of major complications.